01Dec
Americas Antitrust Review 2021
Covid-19 has made 2020 into a year like no other with ‘stay at home’ orders and working from home the new normal. Nonetheless, the tech and pharma industries continued to attract immense antitrust scrutiny, with daily reports in the media and pressure from politicians to address what some perceive to be anticompetitive mergers by digital platforms and pharmaceutical companies, even while innovation in both sectors continues at breakneck speed. In this article, we discuss some of the most...
By:
Cooley LLP
Related
Control over pre-packs looks set to tighten further - As we stand looking into the abyss of another...
Read More >
The National Labor Relations Board in recent weeks has continued to overturn Board decisions from Pr...
Read More >
Following the February 13, 2020 effective date of the U.S. Department of Treasury's final regulation...
Read More >
A great deal has been written about the M&A wars, including our prior alerts regarding the issues th...
Read More >
The Fifth Circuit Court of Appeals recently handed employers an important legal victory with respect...
Read More >
As the COVID-19 virus continues to spread, developers, contractors, and subcontractors are increasin...
Read More >